Entering text into the input field will update the search result below

ZIOPHARM poised to advance lead gene therapy candidate into Phase 3; shares ahead 5% premarket

Mar. 27, 2017 8:55 AM ETAlaunos Therapeutics, Inc. (TCRT) StockBy: Douglas W. House, SA News Editor9 Comments
  • ZIOPHARM Oncology (ZIOP) perks up 5% premarket on light volume on the heels of its announcement that it has received FDA guidance from an End-of-Phase 2 meeting regarding lead gene therapy candidate Ad-RTS-hIL-12, in combination with orally administered veledimex, for the treatment of an aggressive type of brain cancer called recurrent glioblastoma (GBM).
  • The company plans to advance the gene therapy, which utilizes its RheoSwitch platform, into Phase 3 development this year. It will release details about the protocol design after completed discussions with clinical advisors and regulators.
  • Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of interleukin-12 (IL-12), an essential protein for stimulating a T cell immune response to cancer. Veledimex is an oral activator ligand or "gene switch" which is used to control the expression of IL-12, a pro-inflammatory cytokine that produces serious side effects if over-expressed.

Recommended For You

About TCRT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TCRT--
Alaunos Therapeutics, Inc.